Lulizumab pegol, a pegylated Domain Antibody® targeting CD28 developed by Bristol-Myers Squibb, was evaluated in a phase II trial in subjects with active systemic lupus erythematosus (SLE). The gene discussed is CD28; the disease is systemic lupus erythematosus.